97 related articles for article (PubMed ID: 33891667)
1. Protective effects of klotho on palmitate-induced podocyte injury in diabetic nephropathy.
Suk Kang J; Son SS; Lee JH; Lee SW; Jeong AR; Lee ES; Cha SK; Chung CH; Lee EY
PLoS One; 2021; 16(4):e0250666. PubMed ID: 33891667
[TBL] [Abstract][Full Text] [Related]
2. Klotho Stabilizes the Podocyte Actin Cytoskeleton in Idiopathic Membranous Nephropathy through Regulating the TRPC6/CatL Pathway.
Wang H; Liu H; Cheng H; Xue X; Ge Y; Wang X; Yuan J
Am J Nephrol; 2024; 55(3):345-360. PubMed ID: 38330925
[TBL] [Abstract][Full Text] [Related]
3. The redox-sensitive GSK3β is a key regulator of glomerular podocyte injury in type 2 diabetic kidney disease.
Chen M; Fang Y; Ge Y; Qiu S; Dworkin L; Gong R
Redox Biol; 2024 Jun; 72():103127. PubMed ID: 38527400
[TBL] [Abstract][Full Text] [Related]
4. ADAM10 as a major activator of reactive oxygen species production and klotho shedding in podocytes under diabetic conditions.
Piwkowska A; Rachubik P; Typiak M; Kulesza T; Audzeyenka I; Saleem MA; Gruba N; Wysocka M; Lesner A; Rogacka D
Biochem Pharmacol; 2024 Jul; 225():116328. PubMed ID: 38815628
[TBL] [Abstract][Full Text] [Related]
5. Klotho May Ameliorate Proteinuria by Targeting TRPC6 Channels in Podocytes.
Kim JH; Xie J; Hwang KH; Wu YL; Oliver N; Eom M; Park KS; Barrezueta N; Kong ID; Fracasso RP; Huang CL; Cha SK
J Am Soc Nephrol; 2017 Jan; 28(1):140-151. PubMed ID: 27151926
[TBL] [Abstract][Full Text] [Related]
6.
Li H; Zheng J; Wu Y; Zhou H; Zeng S; Li Q
Aging (Albany NY); 2023 Oct; 15(19):10291-10306. PubMed ID: 37812195
[TBL] [Abstract][Full Text] [Related]
7. Klotho inhibits renal ox-LDL deposition via IGF-1R/RAC1/OLR1 signaling to ameliorate podocyte injury in diabetic kidney disease.
Jiang W; Gan C; Zhou X; Yang Q; Chen D; Xiao H; Dai L; Chen Y; Wang M; Yang H; Li Q
Cardiovasc Diabetol; 2023 Oct; 22(1):293. PubMed ID: 37891556
[TBL] [Abstract][Full Text] [Related]
8. CDDO-Me ameliorates podocyte injury through anti-oxidative stress and regulation of actin cytoskeleton in adriamycin nephropathy.
Xu C; Liu X; Zhai X; Wang G; Qin W; Cheng Z; Chen Z
Biomed Pharmacother; 2023 Nov; 167():115617. PubMed ID: 37801905
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase 9 exacerbates podocyte injury in hyperhomocysteinemia through epigenetic repression of Klotho.
Liu M; Zhang Y; Zhan P; Sun W; Dong C; Liu X; Yang Y; Wang X; Xie Y; Gao C; Hu H; Shi B; Wang Z; Guo C; Yi F
Pharmacol Res; 2023 Dec; 198():107009. PubMed ID: 37995896
[TBL] [Abstract][Full Text] [Related]
10. The interaction between klotho protein and epigenetic alteration in diabetes and treatment options.
Hosseininasab SS; Dhiaa SM; Shahrtash SA; Lak M; Faghihkhorasani A; Mahdi F
J Diabetes Metab Disord; 2024 Jun; 23(1):333-341. PubMed ID: 38932867
[TBL] [Abstract][Full Text] [Related]
11. Silencing of miR-150-5p Ameliorates Diabetic Nephropathy by Targeting SIRT1/p53/AMPK Pathway.
Dong W; Zhang H; Zhao C; Luo Y; Chen Y
Front Physiol; 2021; 12():624989. PubMed ID: 33897448
[TBL] [Abstract][Full Text] [Related]
12. Klotho-derived peptide 6 ameliorates diabetic kidney disease by targeting Wnt/β-catenin signaling.
Chen X; Tan H; Xu J; Tian Y; Yuan Q; Zuo Y; Chen Q; Hong X; Fu H; Hou FF; Zhou L; Liu Y
Kidney Int; 2022 Sep; 102(3):506-520. PubMed ID: 35644285
[TBL] [Abstract][Full Text] [Related]
13. Klotho Ameliorates Podocyte Injury through Targeting TRPC6 Channel in Diabetic Nephropathy.
Yao X; Guo H; Sun M; Meng S; Zhu B; Fang J; Huang J; Wang H; Xing L
J Diabetes Res; 2022; 2022():1329380. PubMed ID: 35480629
[TBL] [Abstract][Full Text] [Related]
14. Impact of klotho on the expression of SRGAP2a in podocytes in diabetic nephropathy.
Jin D; Jia M; Xie Y; Lin L; Qiu H; Lu G
BMC Nephrol; 2022 Apr; 23(1):151. PubMed ID: 35436879
[TBL] [Abstract][Full Text] [Related]
15. Klotho protects against diabetic kidney disease via AMPK- and ERK-mediated autophagy.
Xue M; Yang F; Le Y; Yang Y; Wang B; Jia Y; Zheng Z; Xue Y
Acta Diabetol; 2021 Oct; 58(10):1413-1423. PubMed ID: 34046744
[TBL] [Abstract][Full Text] [Related]
16. CD36-mediated podocyte lipotoxicity promotes foot process effacement.
Hua W; Peng L; Chen XM; Jiang X; Hu J; Jiang XH; Xiang X; Wan J; Long Y; Xiong J; Ma X; Du X
Open Med (Wars); 2024; 19(1):20240918. PubMed ID: 38584832
[TBL] [Abstract][Full Text] [Related]
17. Cytoskeleton Rearrangement in Podocytopathies: An Update.
Ma S; Qiu Y; Zhang C
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203817
[TBL] [Abstract][Full Text] [Related]
18. In vivo safety and biodistribution profile of Klotho-enhanced human urine-derived stem cells for clinical application.
Kim SH; Lee SH; Jin JA; So HJ; Lee JU; Ji MJ; Kwon EJ; Han PS; Lee HK; Kang TW
Stem Cell Res Ther; 2023 Dec; 14(1):355. PubMed ID: 38072946
[TBL] [Abstract][Full Text] [Related]
19. Potential application of Klotho as a prognostic biomarker for patients with diabetic kidney disease: a meta-analysis of clinical studies.
Yu LX; Sha MY; Chen Y; Tan F; Liu X; Li S; Liu QF
Ther Adv Chronic Dis; 2023; 14():20406223231213246. PubMed ID: 38058396
[TBL] [Abstract][Full Text] [Related]
20. Triptolide protects against podocyte injury in diabetic nephropathy by activating the Nrf2/HO-1 pathway and inhibiting the NLRP3 inflammasome pathway.
Lv C; Cheng T; Zhang B; Sun K; Lu K
Ren Fail; 2023 Dec; 45(1):2165103. PubMed ID: 36938748
[No Abstract] [Full Text] [Related]
[Next] [New Search]
